1
|
Arrieta-Bolaños E, Mayor NP, Marsh SGE, Madrigal JA, Apperley JF, Kirkland K, Mackinnon S, Marks DI, McQuaker G, Perry J, Potter MN, Russell NH, Thomson K, Shaw BE. Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors. Haematologica 2015; 101:382-90. [PMID: 26611472 DOI: 10.3324/haematol.2015.134999] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2015] [Accepted: 11/20/2015] [Indexed: 12/12/2022] Open
Abstract
Transforming growth factor β-1, encoded by the TGFB1 gene, is a cytokine that plays a central role in many physiological and pathogenic processes. We have sequenced TGFB1 regulatory region and assigned allelic genotypes in a large cohort of hematopoietic stem cell transplantation patients and donors. In this study, we analyzed 522 unrelated donor-patient pairs and examined the combined effect of all the common polymorphisms in this genomic region. In univariate analysis, we found that patients carrying a specific allele, 'p001', showed significantly reduced overall survival (5-year overall survival 30.7% for p001/p001 patients vs. 41.6% others; P=0.032) and increased non-relapse mortality (1-year non-relapse mortality: 39.0% vs. 25.4%; P=0.039) after transplantation. In multivariate analysis, the presence of a p001/p001 genotype in patients was confirmed as an independent factor for reduced overall survival [hazard ratio=1.53 (1.04-2.24); P=0.031], and increased non-relapse mortality [hazard ratio=1.73 (1.06-2.83); P=0.030]. In functional experiments we found a trend towards a higher percentage of surface transforming growth factor β-1-positive regulatory T cells after activation when the cells had a p001 allele (P=0.07). Higher or lower production of transforming growth factor β-1 in the inflammatory context of hematopoietic stem cell transplantation may influence the development of complications in these patients. Findings indicate that TGFB1 genotype could potentially be of use as a prognostic factor in hematopoietic stem cell transplantation risk assessment algorithms.
Collapse
Affiliation(s)
- Esteban Arrieta-Bolaños
- Anthony Nolan Research Institute, London, UK Cancer Institute, University College London, UK Centro de Investigaciones en Hematología y Trastornos Afines (CIHATA), Universidad de Costa Rica, San José, Costa Rica
| | - Neema P Mayor
- Anthony Nolan Research Institute, London, UK Cancer Institute, University College London, UK
| | - Steven G E Marsh
- Anthony Nolan Research Institute, London, UK Cancer Institute, University College London, UK
| | - J Alejandro Madrigal
- Anthony Nolan Research Institute, London, UK Cancer Institute, University College London, UK
| | | | | | - Stephen Mackinnon
- Department of Haematology, University College London, Royal Free Campus, UK
| | - David I Marks
- Adult BMT Unit, University Hospitals Bristol NHS Trust, Bristol, UK
| | - Grant McQuaker
- Bone Marrow Transplant Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - Julia Perry
- BSBMT Data Registry, Guy's Hospital, London, UK
| | | | - Nigel H Russell
- Centre for Clinical Haematology, Nottingham University Hospital, and Academic Haematology, Nottingham University Hospitals, UK
| | - Kirsty Thomson
- Department of Haematology, University College Hospital, London, UK
| | - Bronwen E Shaw
- Anthony Nolan Research Institute, London, UK Cancer Institute, University College London, UK
| |
Collapse
|